TP53 and urinary bladder carcinoma: Importantly, non-synonymous mutations in known bladder cancer driver genes, such as chromatin remodelling genes and TP53, STAG2 and PIK3CA, have been identified in non-diseased bladders as well as in histologically tumor-free urothelium from patients with bladder cancer (8).